Lucia Bio
Lucia Bio is a biotechnology company that focuses on developing Syk inhibitors that help in the treatment of immunological diseases.
Backed by
Uniquest
UniseedRaised 2M SEED on September 1, 2025
About
Lucia Bio, a Queensland biotech joint venture of Molecule to Medicine and University of Queensland's QEDDI, develops Syk inhibitors for autoimmune diseases and neuroinflammation, including QED-701 and QED-121.
Mission
Lucia Bio is a Queensland biotech joint venture between the UK’s Molecule to Medicine and the University of Queensland’s QEDDI. The company develops Syk inhibitors targeting autoimmune diseases and neuroinflammation, with lead assets QED-701 and QED-121. It recently topped up its seed round with an additional $2M, bringing total capital raised to $3M. The UniQuest Extension Fund and Uniseed-managed funds each contributed $1M to the extension. The article does not provide operating metrics, a valuation, or details of other financing instruments for Lucia Bio.
Quick Facts
Funding
SEED
Industry
Biotechnology, Health Diagnostics
Team Size
1-10
Headquarters
Camberwell, Victoria, Australia
Careers
View Careers Page
Lucia Bio
https://jobs.ashbyhq.com/luciaNo open roles at this time.
Check their careers page for updates